Junction Bioscience
Junction Bioscience is an artificial intelligence company focused on molecular discovery for pharmaceutical development [1]. Founded in 2024, the company develops autonomous AI scientists designed to discover medicines targeting neuroinflammation and immunology [1]. The company's core technology is described as an AI Hypothesis Engine for Molecular Discovery [1][4]. Junction Bioscience is headquartered in New York City, NY [2][5]. The company participated in Y Combinator's Winter 2024 batch [3][6]. According to the company's description, it builds an autonomous AI scientist to navigate medicine discovery, with a scientific hypothesis engine that iterates upon chemistry to clarify the molecular basis of disease, focusing on the intersection of neuroinflammation and immunology [7].
Leadership & org chart
About
- Junction Bioscience is building an autonomous AI scientist to navigate the discovery of transformative medicines. Our scientific hypothesis engine iterates upon breakthrough chemistry from the laboratory to achieve clarity and control over the molecular basis of disease. We focus on the intersection of neuroinflammation and immunology where uncommon molecular insights position us to develop best-in-class therapies for millions of patients in need.[7]
Something wrong or missing? Send a correction. Fixed within 24 hours.